Stock Track | Hims & Hers Health Soars 5.04% in Pre-market After J.P. Morgan Initiates Coverage with Overweight Rating

Stock Track04-24

Hims & Hers Health Inc. (HIMS) experienced a pre-market surge of 5.04% on Friday, following positive analyst coverage from a major investment bank.

The stock's rise comes after J.P. Morgan initiated coverage on the telehealth company with an "overweight" rating and a $35 price target, representing approximately 24% upside from its previous close. Analysts highlighted several positive factors including the potential of the Novo partnership to mark a turning point by removing legal overhang, positioning the company as a comprehensive platform offering branded, generic, and compounded products.

J.P. Morgan also noted that Hims & Hers' weight loss specialty can still grow this year, with more stable GLP-1 business, peptide legalization, revenue reacceleration expected in the second half, and potential for additional branded partnerships creating a compelling catalyst path for the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1106494695?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 20:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106494695","market":"nz","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 5.04% in Pre-market After J.P. Morgan Initiates Coverage with Overweight Rating","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) experienced a pre-market surge of 5.04% on Friday, following positive analyst coverage from a major investment bank.</p><p>The stock's rise comes after J.P. Morgan initiated coverage on the telehealth company with an \"overweight\" rating and a $35 price target, representing approximately 24% upside from its previous close. Analysts highlighted several positive factors including the potential of the Novo partnership to mark a turning point by removing legal overhang, positioning the company as a comprehensive platform offering branded, generic, and compounded products.</p><p>J.P. Morgan also noted that Hims & Hers' weight loss specialty can still grow this year, with more stable GLP-1 business, peptide legalization, revenue reacceleration expected in the second half, and potential for additional branded partnerships creating a compelling catalyst path for the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 5.04% in Pre-market After J.P. Morgan Initiates Coverage with Overweight Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 5.04% in Pre-market After J.P. Morgan Initiates Coverage with Overweight Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-24 20:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) experienced a pre-market surge of 5.04% on Friday, following positive analyst coverage from a major investment bank.</p><p>The stock's rise comes after J.P. Morgan initiated coverage on the telehealth company with an \"overweight\" rating and a $35 price target, representing approximately 24% upside from its previous close. Analysts highlighted several positive factors including the potential of the Novo partnership to mark a turning point by removing legal overhang, positioning the company as a comprehensive platform offering branded, generic, and compounded products.</p><p>J.P. Morgan also noted that Hims & Hers' weight loss specialty can still grow this year, with more stable GLP-1 business, peptide legalization, revenue reacceleration expected in the second half, and potential for additional branded partnerships creating a compelling catalyst path for the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1106494695","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106494695","pubTimestamp":1777033140,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) experienced a pre-market surge of 5.04% on Friday, following positive analyst coverage from a major investment bank.The stock's rise comes after J.P. Morgan initiated...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"个股追踪|摩根大通启动跑赢大盘评级覆盖后，Hims&Hers Health盘前飙升5.04%","themeId":"1b5e0887bced2e980404b6424415259e","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) experienced a pre-market surge of 5.04% on Friday, following positive analyst coverage from a major investment bank.The stock's rise comes after J.P. Morgan initiated coverage on the telehealth company with an \"overweight\" rating and a $35 price target, representing approximately 24% upside from its previous close. Analysts highlighted several positive factors including the potential of the Novo partnership to mark a turning point by removing legal overhang, positioning the company as a comprehensive platform offering branded, generic, and compounded products.J.P. Morgan also noted that Hims & Hers' weight loss specialty can still grow this year, with more stable GLP-1 business, peptide legalization, revenue reacceleration expected in the second half, and potential for additional branded partnerships creating a compelling catalyst path for the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1106494695","isCrawlerRequest":true}